Compare ARVN & IGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARVN | IGR |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 600.2M | 693.0M |
| IPO Year | 2018 | 2003 |
| Metric | ARVN | IGR |
|---|---|---|
| Price | $7.26 | $10.77 |
| Analyst Decision | Buy | |
| Analyst Count | 16 | 0 |
| Target Price | ★ $13.93 | N/A |
| AVG Volume (30 Days) | ★ 646.8K | 497.7K |
| Earning Date | 11-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 13.93% |
| EPS Growth | ★ 58.84 | N/A |
| EPS | ★ 1.70 | N/A |
| Revenue | ★ $262,600,000.00 | N/A |
| Revenue This Year | $12.76 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.54 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.74 | $4.15 |
| 52 Week High | $14.22 | $13.67 |
| Indicator | ARVN | IGR |
|---|---|---|
| Relative Strength Index (RSI) | 43.63 | 49.43 |
| Support Level | $6.74 | $4.54 |
| Resistance Level | $7.74 | $13.67 |
| Average True Range (ATR) | 0.36 | 0.22 |
| MACD | 0.08 | -0.24 |
| Stochastic Oscillator | 51.43 | 19.44 |
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
CBRE Clarion Global Real Estate Income Fund is a United States-based diversified, closed-end management investment company. Its primary objective is high current income, and its secondary objective is capital appreciation. The fund invests a majority of its total assets in income-producing real estate securities, which includes common stocks, preferred securities, warrants, and convertible securities issued by real estate companies, such as real estate investment trusts. Under normal market conditions, it invests in real estate equity securities of companies domiciled predominantly in developed countries.